EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC-ND 4.0

Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea

Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek

Virology Journal · 2024

DOI: 10.1186/s12985-024-02464-1 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Virology Journal, 2024. Verfasst von Sang Yi Moon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan, 49201, South Korea. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, COVID-19, Liver Diseases, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dong-A University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Conflicting evidence exists regarding the effects of ursodeoxycholic acid (UDCA) on coronavirus disease 2019 (COVID-19). This study investigates the association between UDCA administration and COVID-19 infection and its related outcomes in individuals with chronic liver disease (CLD). METHODS: A customized COVID-19 research database (n = 3,485,376) was created by integrating data from the National Health Insurance Service (NHIS) and the Korea Disease Control and Prevention Agency's COVID-19 databases. The study focused on patients diagnosed with COVID-19 in 2021, using the NHIS data from 365 days before diagnosis. To create comparable groups with and without UDCA administration before COVID-19, we used propensity score matching. The primary endpoint was the first confirmed positive result for severe acute respiratory syndrome coronavirus-2. In addition, we identified severe COVID-19-related outcomes. Subgroup analysis were conducted based on the dose of UDCA exposure. RESULTS: Data from 74,074 individuals with CLD was analyzed. The participants' average age was 57.5 years, and 52.1% (19,277) of those in each group were male. Those with prior UDCA exposure had a significantly lower risk of COVID-19 infection (adjusted OR: 0.80, 95% CI [0.76-0.85]) compared to the non-UDCA group. Additionally, the UDCA group had a lower risk of severe COVID-19 outcomes (adjusted OR: 0.67, 95% CI [0.46-0.98]). Subgroup analyses indicated that there was a decrease in COVID-19 infection and its related outcomes with increasing UDCA exposure dose. CONCLUSIONS: Our large observational study highlights the potential use of readily available UDCA as an adjunctive therapy for COVID-19 in individuals with CLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursodeoxycholic AcidCOVID-19Liver DiseasesSARS-CoV-2HumansMaleFemaleRepublic of KoreaMiddle AgedCase-Control StudiesAgedAdultCOVID-19 Drug TreatmentChronic Disease

Stichwörter der Autor:innen

COVID-19SARS-CoV-2UDCA

Substanzen

Ursodeoxycholic Acid

Autor:innen und Institutionen

  • Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan, 49201, South Korea.
  • Department of Data Sciences Convergence, Dong-A University Interdisciplinary Program, Busan, South Korea.
  • Department of Physiology, Dong-A University College of Medicine, Busan, South Korea.
  • Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan, 49201, South Korea. p100100@dau.ac.kr.

Förderung

  • Dong-A University Research Fund

Zitieren

APA

Moon, S. Y., Son, M., Kang, Y. W., Koh, M., Lee, J. Y., & Baek, Y. H. (2024). Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea. Virology Journal. https://doi.org/10.1186/s12985-024-02464-1

Vancouver

Moon SY, Son M, Kang YW, Koh M, Lee JY, Baek YH. Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea. Virology Journal. 2024. doi:10.1186/s12985-024-02464-1

BibTeX
@article{Moon2024,
  author = {Moon, Sang Yi and Son, Minkook and Kang, Yeo Wool and Koh, Myeongseok and Lee, Jong Yoon and Baek, Yang Hyun},
  title = {Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea},
  journal = {Virology Journal},
  year = {2024},
  doi = {10.1186/s12985-024-02464-1}
}
Kostenlos starten →